We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
-6.2%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$4.77B
AUM Growth
-$356M
Cap. Flow
-$1.38B
Cap. Flow %
-28.99%
Top 10 Hldgs %
39.93%
Holding
155
New
23
Increased
16
Reduced
21
Closed
28

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$89.6M
2
AHCO icon
AdaptHealth
AHCO
+$49.8M
3
ESPR
Esperion Therapeutics
ESPR
+$40M
4
XLO icon
Xilio Therapeutics
XLO
+$36.7M
5
FIGS icon
FIGS
FIGS
+$27.3M

Top Sells

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$30.8M
2
MOH icon
Molina Healthcare
MOH
+$28.8M
3
CYTK icon
Cytokinetics
CYTK
+$28.1M
4
XLRN
Acceleron Pharma
XLRN
+$25M
5
FATE icon
Fate Therapeutics
FATE
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 64.78%
2 Miscellaneous 33.33%
3 Financials 1.4%
4 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$368M 7.72%
19,341,024
– –
VTRS icon
2
Viatris
VTRS
$19.4B
$281M 5.9%
20,774,000
+1,950,000
+10% +$26M
AHCO icon
3
AdaptHealth
AHCO
$866M
$250M 5.25%
10,225,445
+2,121,653
+26% +$49.8M
CMAX
4
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$129M 2.7%
559,292
– –
NBIX icon
5
Neurocrine Biosciences
NBIX
$15.8B
$117M 2.46%
1,377,945
+235,530
+21% +$21.7M
OMIC
6
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$105M 2.21%
303,734
– –
CNC icon
7
Centene
CNC
$33.1B
$82.7M 1.73%
1,003,800
– –
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$79.6M 1.67%
4,761,138
-102,587
-2% -$1.68M
ORGO icon
9
Organogenesis Holdings
ORGO
$220M
$78.1M 1.64%
8,456,876
+994,333
+13% +$10.6M
LUNG icon
10
Pulmonx
LUNG
$94.9M
$75.9M 1.59%
2,366,867
+336,980
+17% +$12.3M
SILK
11
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$64.6M 1.36%
1,517,181
+526,930
+53% +$26.4M
LRMR icon
12
Larimar Therapeutics
LRMR
$398M
$62.9M 1.32%
5,830,249
– –
WGS icon
13
GeneDx Holdings
WGS
$2.56B
$62.3M 1.31%
423,237
+3,586
+0.9% +$801K
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.68B
$60.1M 1.26%
3,933,137
– –
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$54.5M 1.14%
5,580,456
+4,765,456
+585% +$89.6M
APR
16
DELISTED
Apria, Inc. Common Stock
APR
$54M 1.13%
1,655,795
+238,095
+17% +$7.72M
MIRM icon
17
Mirum Pharmaceuticals
MIRM
$6.14B
$52.4M 1.1%
3,282,912
– –
GKOS icon
18
Glaukos
GKOS
$10.5B
$51.6M 1.08%
1,161,414
+542,414
+88% +$25M
KURA icon
19
Kura Oncology
KURA
$1.18B
$49.2M 1.03%
3,513,756
+1,198,339
+52% +$19.4M
MOH icon
20
Molina Healthcare
MOH
$10.5B
$42.9M 0.9%
134,989
-96,787
-42% -$28.8M
ATEC icon
21
Alphatec Holdings
ATEC
$1.46B
$41.1M 0.86%
3,594,829
– –
PTGX icon
22
Protagonist Therapeutics
PTGX
$9.43B
$40.1M 0.84%
1,172,943
-221,057
-16% -$6.99M
DAWN
23
DELISTED
Day One Biopharmaceuticals
DAWN
$37.1M 0.78%
2,202,533
+491,803
+29% +$10.1M
CYTK icon
24
Cytokinetics
CYTK
$10.1B
$36.9M 0.77%
809,000
-727,758
-47% -$28.1M
PCRX icon
25
Pacira BioSciences
PCRX
$1.05B
$35.9M 0.75%
596,338
-370,898
-38% -$20.5M
1
2 3 4 5

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q4 2021 Portfolio in Review

As of Q4 2021, Deerfield Management held 155 positions worth $4.77B, down 7% from $5.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deerfield Management withdrew a net $1.38B in Q4 2021, closing 28 positions and reducing 21 holdings. Its most notable exit was Acceleron Pharma, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 68% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Deerfield Management opened a new position in Esperion Therapeutics worth $25M.

  • Deerfield Management's largest Q4 2021 buy was Esperion Therapeutics: 5,000,000 shares worth $25M.
  • Deerfield Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, an estimated $89.6M increase.
  • Deerfield Management's biggest Q4 2021 reduction was BioDelivery Sciences International, Inc., cutting an estimated $30.8M.
  • Deerfield Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $25M.
  • Deerfield Management's ten largest holdings make up 40% of its $4.77B portfolio in Q4 2021.
  • Deerfield Management opened 23 new positions and closed 28 in Q4 2021.
  • Deerfield Management's portfolio value fell 7% quarter-over-quarter to $4.77B.

Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.